Neurocrine Biosciences Inc (NAS:NBIX)
$ 126.59 -1.32 (-1.03%) Market Cap: 12.82 Bil Enterprise Value: 11.84 Bil PE Ratio: 33.94 PB Ratio: 4.71 GF Score: 85/100

Neurocrine Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 05:45PM GMT
Release Date Price: $133.71 (-0.17%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama, I'm one of the senior Biotech Analysts here at JPMorgan. I'm joined by my squad, [Lorea] Hall, Malcolm Kuno, and Priyanka Grover.

Our next presenting company is Neurocrine, and presenting on behalf of the company, we have CEO, Kevin Gorman. Kevin?

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thank you, Anupam, and welcome, everyone. I want to say a big thanks to Anupam and the JPMorgan team for the opportunity to be here today. We -- I will be making forward-looking statements, so I direct you to our more most recent SEC guidelines.

So Neurocrine is a company that has traditionally taken on drug development in areas that have never had drug development before. And I think that, that -- when I show you our pipeline or commercial activities, you'll see that to be true.

And that is something that we feel passionately about. It's not that we -- all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot